Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).The analyst commented, “KALV held a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE